Ferring opens manufacturing site in China

Ferring Pharmaceutical (China) has celebrated the grand opening of its manufacturing site in Zhongshan port, the company's first production site in Asia.

Opened on 23 March 2005, the two-storey, GMP-compliant manufacturing plant comprises 20,000 m2, and is factory equipped with multiple production lines, including solutions for injection, lyophilized products, granules and enema, which will strengthen and facilitate Ferring's business development in Asia.

With in-house production sites in Europe, research centres in the US and UK, the new Zhongshan plant in China, and a large-scale manufacturing plant being built in Saint-Prex, Switzerland, Ferring has became a pioneer in developing and selling pharmaceutical products based upon natural pituitary-produced pep-tide hormones, serving patients in over 70 countries.

The completion of the Zhongshan plant not only marks success in business development for Ferring, but a valuable contribution to the pharmaceutical industry in China.

Ferring is a Swiss-based research driven, speciality biopharmaceutical group active in global markets. The company identifies, develops and markets innovative products in the areas of endocrinology, gastroenterology, gynaecology, infertility and urology.

The late Dr. Frederick Paulsen, the founder of Ferring, was one of the first scientists to study and develop peptide hormone, believing that that they could be used to supplement deficiencies and thus play an important role in the treatment of various life-threatening diseases. His theory has been proven to be remarkably accurate, and over the past five decades the company has grown from his original research, most recently expandeing beyond its tradi-tional European base to have operating subsidiaries in over 40 countries.